32 FS tanısı alan hasta ile 28 sağlıklı kontrol çalışma kapsamına alındı, yaş ortalamaları sırasıyla 32.6 ± 7.8 ve 38.8 ± 11.1 yıl idi. Hasta ve kontrol grubunun yaygın ağrı, hassas nokta sayısı ve eşlik eden semptomları gibi demografik ve klinik özellikleri kaydedildi. Hipermobilite tanısı Beighton skorlama yöntemine göre, BEHMS tanısı ise 1998 Brighton kriterlerine göre konuldu.

Hasta grubunda ortalama hassas nokta sayısı, eşlik eden semptom sayısı ve Beighton skoru sırasıyla 14.7 ± 1.9; 7.1 ± 1.7 ve 3.4 ± 1.3 olarak bulundu. Kontrol grubunda ise ortalama hassas nokta sayısı, eşlik eden semptom sayısı ve Beighton skoru sırasıyla 2.5 ± 3.1; 2.5 ± 1.6 ve 1.7 ± 1.9 idi. BEHMS hasta grubunda 2 (5.8 %) kontrol grubunda ise 1 (2.9 %) olguda tespit edildi.

Sonuç olarak fibromiyalji sendromlu hastalar kontrol grubuna göre daha hipermobil olmalarına rağmen BEHMS, FS ile ilişkisi olmayan farklı bir klinik tablodur.

30 fibromyalgia patients and 28 healthy controls subjects with a mean age of 32.6 ± 7.8 and 38.8 ± 11.1 years respectively, were recruited to the study. Data about demographical and clinical characteristics of the patients including widespread pain, number of specific tender points and associated symptoms were recorded. The joint hypermobility was evaluated depending on the Beighton score and the diagnosis of BJHS was considered according to the revised criteria for the diagnosis of BJHS (Brighton 1998).

The mean number of tender points, associated symptoms and Beighton score in the patient group were 14.7 ± 1.9, 7.1 ± 1.7 and 3.4 ± 1.3 respectively. The mean number of tender points, associated symptoms and Beighton score in the control group were 2.5 ± 3.1, 2.5 ± 1.6 and 1.7 ± 1.9 respectively. Beighton scores were significantly high in the patients group compared to control subjects (p< 0.05). The BJHS was present in 2 (5.8 %) of FS and 1 (2.9 %) of the control patients, the difference was not statistically significant (p>0.05).

As a result, the fibromyalgia patients may be more hypermobile than the control subjects but BJHS is a different clinical entity having no relationship with FS.